<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title></title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt; font-weight:bold">Improving the utility of surveillance data for antibiotic usage and resistance </span><span style="font-family:Arial; font-size:12pt; font-weight:bold">monitoring </span><span style="font-family:Arial; font-size:12pt; font-weight:bold">and for healthcare associated infection</span><span style="font-family:Arial; font-size:12pt; font-weight:bold"> prevention and control</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt; font-style:italic">A group of experts in antibiotic resistance and healthcare associated infection</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Background</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">There is a renewed focus on the risks posed to public health by antimicrobial resistance. The Chief Medical Officer’s 2013 report warned that antimicrobial resistance</span><span style="font-family:Arial; font-size:11pt"> </span><span style="font-family:Arial; font-size:11pt">is a more serious issue than global warming and </span><span style="font-family:Arial; font-size:11pt">called for it to </span><span style="font-family:Arial; font-size:11pt">be included on the Government’s National Security Risk Assessment.</span><a name="_ednref1"></a><a href="#_edn1">[i]</a><span style="font-family:Arial; font-size:11pt"> Recently we have also seen the publication of the Government’s Five Year AMR Strategy.</span><a name="_ednref2"></a><a href="#_edn2">[ii]</a><span style="font-family:Arial; font-size:11pt"> This aims to improve knowledge and understanding of AMR, conserve the effectiveness of existing treatments and stimulate the development of new antibiotics.  Although the strategy is welcome, there is still a great deal of work to be done to ensure these ambitious aims are achieved. </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">Since 2007, the NHS has focused on measures to reduce two healthcare associated infections (HCAIs), MRSA blood stream infections (BSIs) and </span><span style="font-family:Arial; font-size:11pt; font-style:italic">Clostridium </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> </span><span style="font-family:Arial; font-size:11pt">(</span><span style="font-family:Arial; font-size:11pt; font-style:italic">C. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt">) infections, and has implemented strict targets and objectives to help drive down rates. A multi-faceted approach that has included both infection control and antimicrobial prescribing measures has been associated with declining rates of these infections, though the effect of specific interventions remains subject to debate.</span><a name="_ednref3"></a><a href="#_edn3">[iii]</a><span style="font-family:Arial; font-size:11pt"> However, there have been some unintended consequences to these control measures, which require a modified approach to maintain improvements and to address emerging infection and antimicrobial resistance threats.</span><span style="font-family:Arial; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">During the period of successful control of MRSA BSIs and </span><span style="font-family:Arial; font-size:11pt; font-style:italic">C. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> </span><span style="font-family:Arial; font-size:11pt">infections, Gram-negative infections, including </span><span style="font-family:Arial; font-size:11pt; font-style:italic">E</span><span style="font-family:Arial; font-size:11pt; font-style:italic">scherichia</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> coli</span><span style="font-family:Arial; font-size:11pt"> </span><span style="font-family:Arial; font-size:11pt">(</span><span style="font-family:Arial; font-size:11pt; font-style:italic">E. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">coli</span><span style="font-family:Arial; font-size:11pt">) </span><span style="font-family:Arial; font-size:11pt">BSIs</span><span style="font-family:Arial; font-size:11pt">, have become a greater </span><span style="font-family:Arial; font-size:11pt">challenge. R</span><span style="font-family:Arial; font-size:11pt">ecent Health Protection Agency (now part of Public Health England) figures show that </span><span style="font-family:Arial; font-size:11pt; font-style:italic">E. coli </span><span style="font-family:Arial; font-size:11pt">BSI</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> </span><span style="font-family:Arial; font-size:11pt">rates increased by 35% in the last five years</span><span style="font-family:Arial; font-size:11pt">,</span><a name="_ednref4"></a><a href="#_edn4">[iv]</a><span style="font-family:Arial; font-size:11pt"> and there were  32,307 mandatory reported cases in England between July 2012 and June 2013. </span><span style="font-family:Arial; font-size:11pt"> Consequently, the CMO called for an expansion of the focus on HCAIs to include other significant infections, which could help reduce resistance to critically important antibiotics, including </span><span style="font-family:Arial; font-size:11pt">carbapenems</span><span style="font-family:Arial; font-size:11pt">.</span><a name="_ednref5"></a><a href="#_edn5">[v]</a></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">In order to address the need for further improvements, </span><span style="font-family:Arial; font-size:11pt">a group of experts in antibiotic resistance and healthcare associated infection</span><span style="font-family:Arial; font-size:11pt">, supported by Astra Zeneca UK, have come together to consider improvements that can be made. This group of experts</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:11pt">agreed</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:11pt">the following recommendations in order to improve clinical practice and patient safety.</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Need for change</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">We</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:11pt">believe that there is a real need to improve the utility of data available to the NHS and clinicians, so that there is greater understanding of current antibiotic prescribing practice with clearer links to patient outcomes.</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">We are concerned about perverse antibiotic prescribing </span><span style="font-family:Arial; font-size:11pt">behaviours</span><span style="font-family:Arial; font-size:11pt"> that are being driven by existing MRSA BSI and </span><span style="font-family:Arial; font-size:11pt; font-style:italic">C. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> </span><span style="font-family:Arial; font-size:11pt">infection objectives/targets.  Whilst avoiding the use of certain antibiotics is sensible in patients at high risk of MRSA or </span><span style="font-family:Arial; font-size:11pt; font-style:italic">C. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt; font-style:italic"> </span><span style="font-family:Arial; font-size:11pt">infection, antibiotic prescribing has become too concentrated on a limited number of drugs.  There is evidence that such intensive use of few antibiotics, rather than using a wide range of agents, can lead to the emergence of resistance, particularly in prob</span><span style="font-family:Arial; font-size:11pt">lematic Gram-negative pathogens (particularly </span><span style="font-family:Arial; font-size:11pt">piperacillin-tazobactam</span><span style="font-family:Arial; font-size:11pt"> and </span><span style="font-family:Arial; font-size:11pt">carbapenems</span><span style="font-family:Arial; font-size:11pt">.)</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">We believe that changing the focus of the current HCAI targets can improve patient care.  The</span><span style="font-family:Arial; font-size:11pt"> following measures would refine</span><span style="font-family:Arial; font-size:11pt"> current implicit and explicit restrictions on antimicrobial </span><span style="font-family:Arial; font-size:11pt">prescribing.  If supported by high quality data, this would empower specialists to recommend the most appropriate antibiotic for patients at the most appropriate time, while still taking into account HCAI and antimicrobial resistance challenges. </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">We therefore call for </span><span style="font-family:Arial; font-size:11pt">three</span><span style="font-family:Arial; font-size:11pt"> measures to drive high quality antibiotic prescribing, which aim to improve patient outcomes and to protect the efficacy of existing antibiotics:</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Arial; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 14.17pt; padding-left:3.83pt; text-indent:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Improved data collection and through electronic prescribing</span><span style="font-family:Arial; font-size:11pt">,</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> accompanied by data analysis</span><span style="font-family:Arial; font-size:11pt">, </span><span style="font-family:Arial; font-size:11pt; font-weight:bold">with clear links to patient outcomes.</span><span style="font-family:Arial; font-size:11pt"> </span><span style="font-family:Arial; font-size:11pt">New ways to monitor antibiotic use should be developed, </span><span style="font-family:Arial; font-size:11pt">which should</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:11pt">record the amounts and types of antibiotics being used, and importantly should measure both the appropriateness and diversity of prescribing and associated antimicrobial resistance.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Arial; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 14.17pt; padding-left:3.83pt; text-indent:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Broaden the focus of HCAI improvement objectives to include other significant infections, such as Gram-negative infections and urinary or intravascular catheter infections, with a greater focus on multi-drug resistant infections, especially those resistant to critical antibiotics.</span><span style="font-family:Arial; font-size:11pt"> Rather than maintain a narrow focus on MRSA and </span><span style="font-family:Arial; font-size:11pt; font-style:italic">C. </span><span style="font-family:Arial; font-size:11pt; font-style:italic">difficile</span><span style="font-family:Arial; font-size:11pt; font-style:italic">,</span><span style="font-family:Arial; font-size:11pt"> a broader composite HCAI objective would give a more accurate measurement of avoidable HCAIs.</span></li></ol><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:Arial; font-size:11pt; font-weight:bold; margin:0pt 0pt 0pt 14.17pt; padding-left:3.83pt; text-indent:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Rationalize the penalties for breaches of HCAI targets.</span><span style="font-family:Arial; font-size:11pt">  </span><span style="font-family:Arial; font-size:11pt">In place of the current potential large fines for missing HCAI objectives/targets, incentives should be considered to encourage high quality antibiotic prescribing and HCAI outcomes.  Hospitals should be required to publish their HCAI rates in standard, easy to understand way, on the NHS Choices website.  This kind of open data reporting would enable patients and referring GPs to make informed choices about treatment options.</span><span style="font-family:Arial; font-size:11pt"> </span></li></ol><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt; font-weight:bold">Conclusion</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">Antimicrobial resistance is one of the biggest public health threats.  </span><span style="font-family:Arial; font-size:11pt">A group of experts in antibiotic resistance and healthcare associated infection </span><span style="font-family:Arial; font-size:11pt">is</span><span style="font-family:Arial; font-size:11pt; font-weight:bold"> </span><span style="font-family:Arial; font-size:11pt">calling for changes to establish an environment whereby infection specialists can make the best prescribing decisions for patients.  Diverse (but appropriate) antibiotic prescribing can reduce the selection pressure for resistance and can improve outcomes for current and future patients.</span></p><p style="margin:0pt 0pt 0pt 18pt; text-align:right"><span style="font-family:Arial; font-size:11pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:11pt">For further information, please contact Professor Mark Wilcox on </span><a href="mailto:mark.wilcox@leedsth.nhs.uk"><span style="color:#0000ff; font-family:Arial; font-size:11pt; text-decoration:underline">mark.wilcox@leedsth.nhs.uk</span></a><span style="font-family:Arial; font-size:11pt"> </span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:10pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_edn1"></a><a href="#_ednref1">[i]</a><span style="font-family:Arial; font-size:9pt"> </span><span style="font-family:Arial; font-size:9pt">House of Commons Science and Technology Committee,  Uncorrected Transcript Of Oral Evidence from the Chief Medical Officer, Department of Health, HC 921-I, Published 11</span><span style="font-family:Arial; font-size:6pt; vertical-align:super">th</span><span style="font-family:Arial; font-size:9pt"> February 2013</span></p><p style="margin:0pt"><a href="http://www.publications.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm"><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">http://www.publication</span><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">s</span><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">.parliament.uk/pa/cm201213/cmselect/cmsctech/uc921-i/uc92101.htm</span></a><span style="font-family:Arial; font-size:9pt"> </span></p><p style="margin:0pt"><a name="_edn2"></a><a href="#_ednref2">[ii]</a><span style="font-family:Arial; font-size:9pt"> </span><span style="font-family:Arial; font-size:9pt">UK Five Year Antimicrobial Resistance Strategy 2013 to 2018, Department of Health, September 2013  </span><a href="https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf"><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/238872/20130902_UK_5_year_AMR_strategy_FINAL.pdf</span></a><span style="font-family:Arial; font-size:9pt"> </span></p><p style="margin:0pt"><a name="_edn3"></a><a href="#_ednref3">[iii]</a><span style="font-family:Arial; font-size:9pt"> Health Protection Agency, Healthcare-Associated Infection and Antimicrobial Resistance: 2010-2011, August 2012 </span><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912"><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136146912</span></a><span style="font-family:Arial; font-size:9pt"> </span></p><p style="margin:0pt"><a name="_edn4"></a><a href="#_ednref4">[iv]</a><span style="font-family:Calibri; font-size:6pt; vertical-align:super"> </span><span style="font-family:Arial; font-size:9pt">Health Protection Agency, </span><span style="font-family:Arial; font-size:9pt">Escherichia coli bacteraemia in England, Wales and Northern Ireland, 2007-2011</span><span style="font-family:Arial; font-size:9pt">, </span><span style="font-family:Arial; font-size:9pt">June 2011</span><span style="font-family:Arial; font-size:9pt"> </span></p><p style="margin:0pt"><a href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317134482059"><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317134482059</span></a><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline"> </span></p><p style="margin:0pt"><a name="_edn5"></a><a href="#_ednref5">[v]</a><span style="font-family:Calibri; font-size:10pt"> </span><span style="font-family:Arial; font-size:9pt">Annual Report of the Chief Medical Officer Volume 2, 2011, Infections and the rise of antimicrobial infections</span><span style="font-family:Arial; font-size:9pt">, </span><span style="font-family:Arial; font-size:9pt">March 2013</span></p><p style="margin:0pt"><a href="https://www.wp.dh.gov.uk/publications/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf"><span style="color:#0000ff; font-family:Arial; font-size:9pt; text-decoration:underline">https://www.wp.dh.gov.uk/publications/files/2013/03/CMO-Annual-Report-Volume-2-20111.pdf</span></a></p><p style="margin:0pt"><span style="font-family:Arial; font-size:9pt">&#xa0;</span></p><p style="margin:0pt; text-align:right"><span style="font-family:Arial; font-size:9pt">&#xa0;</span></p><p style="margin:0pt; text-align:right"><span style="font-family:Arial; font-size:9pt">November 2013</span></p></body></html>